Randomized Trialhigh evidence
Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM.
Circulation·August 28, 2026·PMID 42663111
Why it mattersNonobstructive HCM has no approved therapy, and symptoms are driven by diastolic dysfunction and hypercontractility. Aficamten's broad improvements across symptoms, biomarkers, and cardiac mechanics suggest a disease-modifying effect, potentially filling a major treatment gap for this underserved population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled